JMS Co., Ltd. AI Stock Analysis
Want to see JP:7702 full AI Analyst Report?
JMS Co., Ltd. (7702) AI Stock Analysis
JMS Co., Ltd.
(TSE/TYO:7702)
JMS Co. scores poorly, driven primarily by a multi-year deterioration in financial performance: evaporating profitability with a projected FY2026 net loss, declining revenue, margin compression, a ~51% rise in debt, and persistently negative free cash flow. Technicals reinforce the caution, with the stock trading below all major moving averages and a negative MACD indicating a bearish trend. Valuation offers little support — the negative P/E reflects losses, and while the ~4.0% dividend yield appears appealing, weak cash generation raises doubts about its sustainability. A low beta provides some defensiveness, but it does not offset the fundamental risks. Note that earnings call and corporate event data were unavailable and excluded from the scoring.
JMS Co., Ltd. (7702) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 10.20B
- Dividend Yield
- 4.09%
- Average Volume (3M)
- 37.66K
- Price to Earnings (P/E)
- -11.9
- Beta (1Y)
- 0.57
- Revenue Growth
- -3.10%
- EPS Growth
- -645.12%
- Country
- Japan
- Employees
- 4,887
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
JMS Co., Ltd. Business Overview & Revenue Model
Company Description
JMS Co., Ltd., established in 1947 and headquartered in Hiroshima, Japan, specializes in the development, manufacture, distribution, and global trade of a wide array of medical devices and pharmaceuticals. Its extensive product catalog serves both Ja...
How the Company Makes Money
JMS makes money primarily by selling medical devices and associated disposable consumables to healthcare providers and distributors. Its revenue model typically combines (1) sales of durable or semi-durable equipment (devices used in hospitals and cl...
JMS Co., Ltd. Financial Statement Overview
Summary
Financials are weak across all three statements. Profitability has collapsed — net income fell from ¥1.74B in FY2021 to ¥89M in FY2025, with a ¥784M net loss projected for FY2026 on a 4.7% revenue decline. Gross margins compressed to ~23.3% and EBIT margins to under 1%. The balance sheet shows debt rising ~51% to ¥28.0B while equity grew only modestly, lifting debt-to-equity to 0.67, though equity still covers roughly half of total assets. Cash flow is the weakest link: operating cash flow fell to ~¥1.6B, free cash flow has been negative in four of the last five periods, and debt coverage has dropped below 6%, suggesting capex is being debt-funded.
Income Statement
18Very NegativeBalance Sheet
35NegativeCash Flow
22Negative| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 66.02B | 65.84B | 69.75B | 65.29B | 63.74B | 58.17B |
| Gross Profit | 15.75B | 15.36B | 15.93B | 14.09B | 14.60B | 14.27B |
| EBITDA | 4.50B | 4.22B | 4.79B | 4.08B | 4.38B | 4.59B |
| Net Income | -855.00M | -784.00M | 89.00M | -36.00M | 281.00M | 826.00M |
Balance Sheet | ||||||
| Total Assets | 82.92B | 83.07B | 81.43B | 84.71B | 74.41B | 71.97B |
| Cash, Cash Equivalents and Short-Term Investments | 7.48B | 7.72B | 5.51B | 10.31B | 6.33B | 6.81B |
| Total Debt | 25.55B | 28.01B | 24.55B | 26.92B | 19.75B | 18.71B |
| Total Liabilities | 41.01B | 41.27B | 40.50B | 43.96B | 35.70B | 34.87B |
| Stockholders Equity | 41.86B | 41.73B | 40.84B | 40.57B | 38.53B | 36.96B |
Cash Flow | ||||||
| Free Cash Flow | 0 | -892.00M | -1.42B | 498.00M | -1.07B | 1.14B |
| Operating Cash Flow | 0 | 1.58B | 1.47B | 3.14B | 2.48B | 4.40B |
| Investing Cash Flow | 0 | -2.25B | -3.14B | -4.24B | -3.69B | -3.68B |
| Financing Cash Flow | 0 | 2.69B | -3.19B | 4.78B | 525.00M | -499.00M |
JMS Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7702, the sentiment is Negative. The current price of 416.00 is below the 20-day moving average (MA) of 429.90, below the 50-day MA of 440.64, and below the 200-day MA of 434.03, indicating a bearish trend. The MACD of -5.83 indicates Positive momentum. The RSI at 37.22 is Neutral, neither overbought nor oversold. The STOCH value of 12.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:7702.
JMS Co., Ltd. Peers Comparison
Overall Rating
JP:774775Outperform
JP:454371Outperform
JP:773365Neutral
JP:808652Neutral
JP:770234Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 75Outperform | JPY 1.15T | 32.42 | 21.31% | 1.11% | 22.57% | 138.10% | |
| 71Outperform | JPY 3.85T | 33.07 | 7.14% | 1.30% | 14.97% | -12.99% | |
| 65Neutral | JPY 2.04T | 21.78 | 11.80% | 3.27% | 9.03% | -2.99% | |
| 52Neutral | JPY 270.15B | 22.00 | 3.85% | 2.13% | 5.03% | 0.04% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 34Underperform | JPY 10.31B | -11.93 | ― | 4.09% | -3.10% | -645.12% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:7702 | JMS Co., Ltd. | 416.00 | 2.96 | 0.72% | |
| JP:4543 | Terumo | 2547.00 | 123.52 | 5.10% | |
| JP:7747 | Asahi Intecc Co | 4348.00 | 1492.47 | 52.27% | |
| JP:8086 | Nipro Corporation | 1456.50 | -2.29 | -0.16% | |
| JP:7733 | Olympus Corp | 1833.00 | -167.72 | -8.38% |
JMS Co., Ltd. Corporate Events
JMS Sales Rise Slightly as Net Loss Widens
JMS Co., Ltd. reported consolidated sales of ¥32.391 billion for the six months ended September 2026, up 0.5% year on year, while operating profit improved to ¥9 million from a ¥19 million loss. However, ordinary loss widened to ¥145 million from ¥46...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 17, 2026
